Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases

Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Phase II of this collaboration involved YuvaBio compiling a selection of small molecule candidates with the potential of promoting mitochondrial health to combat obesity an ...